



<b>Indikation:</b>	<b>Studientitel:</b>	<b>Leiter Klinische Prüfung:</b>	<b>Ansprechpartner:</b>
allogene Stammzell-transplantation	Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02).	Prof. Dr. med. Nicolaus Kröger	Prof. Dr. med. Wolfgang Bethge, Tübingen
allogene Stammzell-transplantation	Registry of the therapeutic impact and quality of life of patients with graft versus host disease undergoing extracorporeal photopheresis.	Prof. Dr. med. Wolfgang Bethge, Tübingen	Prof. Dr. med. Wolfgang Bethge, Tübingen
allogene Stammzell-transplantation	Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML. (ETAL3-ASAP).	Prof. Dr. med. Johannes Schetelig, Dresden	Prof. Dr. med. Wolfgang Bethge, Tübingen
allogene Stammzell-transplantation	Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications (PACT2014-001).	PD Dr. med. Götz Ulrich Grigoleit, Würzburg	Prof. Dr. med. Wolfgang Bethge, Tübingen
allogene Stammzell-transplantation	A phase III randomized open-label multicenter study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation (CINC424C2301).	Prof. Dr. med. Nikolas von Bubnoff, Freiburg	Prof. Dr. med. Wolfgang Bethge, Tübingen
allogene Stammzell-transplantation	A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients (SHP620-302)	Prof. Dr. med. Wolfgang Bethge, Tübingen	Prof. Dr. med. Wolfgang Bethge, Tübingen



allogene Stammzell- transplantation	A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir (SHP620-303).	Prof. Dr. med. Wolfgang Bethge, Tübingen	Prof. Dr. med. Wolfgang Bethge, Tübingen
allogene Stammzell- transplantation	A randomized controlled trial comparing outcome after hematopoietic cell transplantation from a partially matched unrelated versus haploidentical donor (HAMLET).	Prof. Dr. med. Johannes Schetelig Dresden	Prof. Dr. med. Wolfgang Bethge, Tübingen
allogene Stammzell- transplantation	A Phase 3 Study of Itacitinib or Placebo in Combination with Calcineurin Inhibitors as Initial Treatment for Chronic Graft-versus-Host Disease.	Prof. Dr. med. Matthias Stelljes, Münster	Prof. Dr. med. Wolfgang Bethge, Tübingen